THERAPEUTICS   I   PIPELINE

LightOx continue to develop their LXD191 candidate, a light activated chemotherapeutic agent for early stage mouth cancers.

LightOx has shown positive pre-clinical results and are planning on conducting a Phase I safety trial of LXD191 with partners in the UK.
VIEW PIPELINE

Pipeline

Mouth Cancer testing data helps catalyse the development of other clinical targets

LEARN MORE
Therapeutic Areas

LightOx also looks to expand with further candidates in alternative therapeutic areas including Project APOLLO focused on anti-fibrotic phototherapy for the treatment of patients with scleroderma, working with scientists at Radboudumc in The Netherlands.

OUR SOLUTION

LXD191

LightOx are developing a new class of light activated chemotherapy for the treatment of oral cancer. We use photosensitising agents along with light to kill cancer cells.
LEARN MORE
LIGHTOX

Probes

A Unique Range of Molecular Tools for use in Imaging, Therapeutics and Assay Development.
LEARN MORE